Articles by : Sponsored Content,

SPONSORED CONTENT

340B providers are facing an unprecedented number of challenges. 340B program managers are forced to react to these changes every day. Having access to clear and understandable data and developing strong relationships with partners in the 340B supply chain are critical to running an effective program. 340B

SPONSORED CONTENT

Let’s get this right out on the table: At Avita, we believe health care is a human right.

Polarizing politics aside, as an advanced, civilized society, we have an ethical obligation to care for the medical needs of every U.S. citizen compassionately and

SPONSORED CONTENT

Alas, after much deliberation, your covered entity has decided to submit data to 340B ESP. As you embark on this journey, you may be asking yourself: Now what?!?  

As someone who has operated a large 340B program at a DSH hospital and now has the privilege

SPONSORED CONTENT

When large drug manufacturers began restricting 340B drug discounts for contract pharmacies in 2020, Coastal Bend Wellness Foundation (CBWF) decided to pivot from a co-located pharmacy to entity owned. By doing so, the Community Health Center, which provides services to several rural counties

SPONSORED CONTENT

In this webinar session, we’ll teach CEs how to optimally manage your 340B data submission. You’ll learn about pulling TPA claims, submitting data, wholesaler price and pharmacy usage monitoring. We will discuss new developments regarding pharmacy usage vs. purchasing monitoring, and

SPONSORED CONTENT

The 340B ESP price loading process can be complex. If you’re a covered entity who contracts with outside pharmacies, here’s your guide to navigating 340B ESP, starting with the basics. Equip yourself with these tips to troubleshoot any price loading roadblocks you may encounter, and ensure pricing is loaded

SPONSORED CONTENT

If you are reading this article, then you’re likely aware of the 340B drug discount program, the U.S. federal government program that requires drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices.

Covered entities may effectively navigate this incredibly complex program, maximize their benefits,